Recent Updates
Recently added Catalysts

mRNA-2808

Phase 1

Relapsed or Refractory Multiple Myeloma | Small molecule | Oncology |Moderna, Inc.|Last Updated: Jun 29, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment166
FDA Designations
No designations recorded
Clinical trial landscape

mRNA-2808 · 1 trial · 1 indication

Phase 1 1
NCT07116616A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple MyelomaRelapsed or Refractory Multiple Myeloma
RECRUITING166 Analytics
PHASE1RECRUITING
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
NCT07116616166
Unlock trial analytics
Study Endpoints
Primary Endpoints
Number of Participants with Dose-limiting Toxicity
Up to 28 days
Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Up to 15 months
Secondary Endpoints
Maximum Plasma Concentration (Cmax)
Up to 1 year
Area Under the Concentration-time Curve (AUC)
Up to 1 year
Maximum Effect/Concentration of the Expressed Protein (Emax)
Up to 1 year
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
mRNA-2808EXPERIMENTALParticipants will receive mRNA-2808.
Interventions
NameTypeDescription
mRNA-2808DRUGintravenous
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites10

Key Inclusion Criteria: * RRMM with prior exposure to a proteasome inhibitor, an immunomodulatory drug (IMiD), and an anti-cluster of differentiation (CD38) monoclonal antibody. * Measurable disease defined as at least 1 of the following: * Serum M-protein ≥0.5 grams/deciliter * Urine M-protei...

Countries:United States
Unlock Eligibility Criteria
Competitive Landscape -Multiple Myeloma 222 trials (matched to "Relapsed or Refractory Multiple Myeloma")

Top 20 of 26 competitors

CompanyTickerTrialsLead PhaseDrugs
AbbVie, Inc.ABBV16PHASE3Pomalidomide, Dexamethasone, Venetoclax
Bristol-Myers Squibb CompanyBMY18PHASE3Iberdomide, Lenalidomide
Takeda Pharmaceutical Co. Ltd. Sponsored ADRTAK5PHASE3IGI, 10%
GSK plc Sponsored ADRGSK17PHASE3Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
Johnson & JohnsonJNJ28PHASE3Bortezomib, Dexamethasone, Lenalidomide, Cilta-cel, Cyclophosphamide
Regeneron Pharmaceuticals, Inc.REGN11PHASE3Linvoseltamab, Carfilzomib, Daratumumab, Dexamethasone, Pomalidomide
Pfizer Inc.PFE11PHASE3Elranatamab, Lenalidomide
Sanofi SA Sponsored ADRSNY18PHASE3Isatuximab, Dexamethasone, Pomalidomide, Montelukast, Paracetamol / Acetaminophen
AstraZeneca PLCAZN5PHASE3AZD0120, Daratumumab, Carfilzomib, Dexamethasone, Bortezomib
Gilead Sciences, Inc.GILD3PHASE3Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine, Pomalidomide, Bortezomib
Karyopharm Therapeutics, Inc.KPTI6PHASE3Selinexor, Elotuzumab, Pomalidomide, Dexamethasone
Grifols, S.A. Sponsored ADR Class BGRFS1PHASE3Xembify
BioLineRX Ltd. Sponsored ADRBLRX1PHASE3BL-8040 /kg, G-CSF
C4 Therapeutics, Inc.CCCC3PHASE2Cemsidomide, Dexamethasone
Cellectar Biosciences, Inc.CLRB1PHASE2Iopofosine I 131 single dose, Iopofosine I 131 fractionated dose
GeoVax Labs, Inc.GOVX1PHASE2COVID-19 Vaccine, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1
Autolus Therapeutics Plc Sponsored ADRAUTL1PHASE2AUTO CAR T cell therapy
Incyte CorporationINCY2PHASE1Ruxolitinib, Lenalidomide, Methylprednisolone
Moderna, Inc.MRNA2PHASE1mRNA-2808
BeOne Medicines Ltd. Sponsored ADRONC1PHASE1Sonrotoclax, Dexamethasone, Carfilzomib, Daratumumab, Pomalidomide
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWJun 29, 2026NCT07116616lastUpdatePostDate: changed
LOWJun 29, 2026NCT07116616lastUpdatePostDate: changed
LOWMay 26, 2026NCT07116616primaryCompletionDate: changed
LOWMay 24, 2026NCT07116616studyFirstPostDate: changed